CATEGORY
EFPIA
- ABPI
- ACE
- ACIS
- Adelaide
- Aetsa
- Agenas
- AHRQ
- AIFA
- AMNOG
- ANVISA
- AOTMiT
- AQuAS
- Behandlingsraadet
- BfArM
- Biocat
- C2H
- CADTH
- CDC
- CDE
- CMS
- COFEPRIS
- CONITEC
- Digemid
- EFPIA
- EMA
- EPF
- Eucope
- EUnetHTA
- EuropaBio
- European Commission
- Euskadi
- FDA
- FOPH
- G-BA
- Gesundheit Österreich
- HAS
- Health Technology Wales
- Healthcare Improvement Scotland
- HHS
- HIQA
- HTAi
- ICER
- IECS
- IETS
- IHE
- IHEA
- INAHTA
- IQWiG
- ISPOR
- KCE
- Medicaid
- Medicines for Europe
- MHRA
- MSP
- NECA
- NHS
- nHTA
- NICE
- NIH
- NIHO
- NIHR
- NIPH
- NSW Health
- NZa
- OHE
- OYS
- PBS
- pCPA
- Pharmac
- PhRMA
- Salute
- SBU
- Schönermark Kielhorn Collegen
- SGK
- TÄ°TCK
- TLV
- WHO
- ZonMw
- Zorginstituut Nederland
US and China Surge Ahead as Europe’s Pharma R&D Growth Lags
New Guidelines for EU Joint Clinical Assessment Set to Streamline Health Technology Evaluations
EFPIA Urges Reassessment of Urban Wastewater Directive’s Impact on Pharmaceuticals
Balancing Data Anonymisation and Utility in Health Research
Evaluating the Public Health Impact of Clinical Data Disclosure
Enhancing Cancer Screening in the EU: Key Insights from Four Countries
EFPIA’s Position on the Regulation on the European Health Data Space
Clinical Trials Initiative EU-X-CT Aims to Improve Cross-Border Access in Europe
Call for Increased Budget in FP10
Urgent Action on Cardiovascular Health Needed
EFPIA Calls for Competitiveness Strategy in EU Life Sciences
Unequal Medicine Access Across Europe: EFPIA Report Highlights Disparities and Calls for Action
Value of Regulatory Data Protection in European Competitiveness
Pharmaceutical Trade Associations Applaud WHO’s Recognition of EMRN and FDA as Listed Authorities
Enhancing Patient Involvement in Health Technology Assessments Across Europe